CL2021001646A1 - Vectores de orthopoxvirus modificados - Google Patents

Vectores de orthopoxvirus modificados

Info

Publication number
CL2021001646A1
CL2021001646A1 CL2021001646A CL2021001646A CL2021001646A1 CL 2021001646 A1 CL2021001646 A1 CL 2021001646A1 CL 2021001646 A CL2021001646 A CL 2021001646A CL 2021001646 A CL2021001646 A CL 2021001646A CL 2021001646 A1 CL2021001646 A1 CL 2021001646A1
Authority
CL
Chile
Prior art keywords
modified orthopoxvirus
vectors
orthopoxvirus vectors
modified
adaptability
Prior art date
Application number
CL2021001646A
Other languages
English (en)
Spanish (es)
Inventor
John C Bell
Michael S Huh
Matthew Y Tang
Adrian Pelin
Caroline J Breitbach
Michael F Burgess
Steven H Bernstein
Original Assignee
Ottawa Hospital Res Inst
Turnstone Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Hospital Res Inst, Turnstone Biologics Corp filed Critical Ottawa Hospital Res Inst
Publication of CL2021001646A1 publication Critical patent/CL2021001646A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2021001646A 2018-12-21 2021-06-18 Vectores de orthopoxvirus modificados CL2021001646A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862784372P 2018-12-21 2018-12-21
US201962872699P 2019-07-10 2019-07-10
US201962930524P 2019-11-04 2019-11-04

Publications (1)

Publication Number Publication Date
CL2021001646A1 true CL2021001646A1 (es) 2022-02-18

Family

ID=71100021

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001646A CL2021001646A1 (es) 2018-12-21 2021-06-18 Vectores de orthopoxvirus modificados

Country Status (18)

Country Link
US (2) US20220056480A1 (enExample)
EP (2) EP3898997A4 (enExample)
JP (2) JP2022514420A (enExample)
KR (2) KR20210132003A (enExample)
CN (2) CN113661246A (enExample)
AU (2) AU2019404639A1 (enExample)
BR (2) BR112021012078A2 (enExample)
CA (2) CA3124301A1 (enExample)
CL (1) CL2021001646A1 (enExample)
CO (1) CO2021009354A2 (enExample)
EC (1) ECSP21053474A (enExample)
IL (2) IL284180A (enExample)
MX (2) MX2021007438A (enExample)
PE (1) PE20212307A1 (enExample)
PH (1) PH12021551436A1 (enExample)
SG (1) SG11202106460XA (enExample)
TW (1) TW202039851A (enExample)
WO (2) WO2020124273A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10612005B2 (en) 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
JP7724601B2 (ja) 2017-02-03 2025-08-18 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 腫瘍溶解性ウイルス療法
SG11202006457YA (en) 2018-01-05 2020-08-28 Ottawa Hospital Res Inst Modified orthopoxvirus vectors
EP4061417A4 (en) * 2019-11-20 2023-10-11 University of Pittsburgh - of the Commonwealth System of Higher Education VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES
JP6915792B1 (ja) * 2020-10-01 2021-08-04 国立大学法人鳥取大学 広範囲遺伝子欠損を有する腫瘍溶解性ワクシニアウイルス
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도
JP2025503721A (ja) * 2022-01-17 2025-02-04 ノイスコム アーゲー がん治療用免疫刺激タンパク質をコードする組換えオルソポックスウイルスベクター
CN119677861A (zh) * 2022-06-10 2025-03-21 特兰斯吉恩股份有限公司 表达白介素-12的重组病毒
IL318055A (en) * 2022-07-08 2025-02-01 Viromissile Inc ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF
CN119923267A (zh) * 2022-07-27 2025-05-02 阿斯利康(瑞典)有限公司 表达白介素-12的重组病毒与pd-1/pd-l1抑制剂的组合
CN115947797B (zh) * 2022-08-02 2024-07-05 青岛硕景生物科技有限公司 猴痘病毒重组抗原及其应用
WO2024130212A1 (en) 2022-12-16 2024-06-20 Turnstone Biologics Corp. Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors
CN116200349A (zh) * 2023-01-18 2023-06-02 中国医学科学院病原生物学研究所 一种基于改良痘苗病毒天坛株的新型冠状病毒疫苗
CN115927215B (zh) * 2023-01-18 2025-10-17 中国医学科学院病原生物学研究所 一种定向减毒的痘苗病毒疫苗
CN118240879A (zh) * 2023-11-01 2024-06-25 上海市重大传染病和生物安全研究院 骨架质粒、重组质粒以及猴痘病毒颗粒和应用
WO2026047314A1 (en) * 2024-08-28 2026-03-05 University Of Surrey Recombinant vector

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2150495T5 (es) * 1993-05-19 2007-02-16 Schering Corporation Ligandos de flt3 purificados de mamifero y agonistas y antagonistas de los mismos.
KR20120002613A (ko) * 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
AU2003290528A1 (en) * 2002-10-15 2004-05-04 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods and reagents for inducing immunity
RU2503717C2 (ru) * 2007-11-19 2014-01-10 Трансжене Са Поксвирусные онколитические векторы
RS65104B1 (sr) * 2013-08-22 2024-02-29 Univ Pittsburgh Commonwealth Sys Higher Education Onkolitičke imunoterapije
RU2696312C2 (ru) * 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
CN106520778A (zh) * 2015-09-09 2017-03-22 北京锤特生物科技有限公司 改造的白介素12及其在制备治疗肿瘤的药物中的用途
WO2018049248A1 (en) * 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus equipped with bispecific engager molecules
SG11202006457YA (en) * 2018-01-05 2020-08-28 Ottawa Hospital Res Inst Modified orthopoxvirus vectors

Also Published As

Publication number Publication date
EP3898997A1 (en) 2021-10-27
WO2020124273A1 (en) 2020-06-25
WO2020124274A1 (en) 2020-06-25
IL284180A (en) 2021-08-31
CO2021009354A2 (es) 2021-11-19
KR20210132003A (ko) 2021-11-03
AU2019410148A1 (en) 2021-08-12
US20220056480A1 (en) 2022-02-24
BR112021011730A2 (pt) 2021-08-31
TW202039851A (zh) 2020-11-01
EP3898998A4 (en) 2022-10-05
US20220380799A1 (en) 2022-12-01
IL284188A (en) 2021-08-31
MX2021007439A (es) 2021-08-05
EP3898997A4 (en) 2022-11-16
BR112021012078A2 (pt) 2021-08-31
ECSP21053474A (es) 2021-11-18
AU2019404639A1 (en) 2021-08-12
EP3898998A1 (en) 2021-10-27
KR20210132002A (ko) 2021-11-03
PE20212307A1 (es) 2021-12-10
CN113661246A (zh) 2021-11-16
CA3124287A1 (en) 2020-06-25
MX2021007438A (es) 2021-09-21
JP2022514420A (ja) 2022-02-10
JP2022516006A (ja) 2022-02-24
CA3124301A1 (en) 2020-06-25
PH12021551436A1 (en) 2021-12-06
SG11202106460XA (en) 2021-07-29
CN113454231A (zh) 2021-09-28

Similar Documents

Publication Publication Date Title
ECSP21053474A (es) Vectores de orthopoxvirus modificados
MX2020007011A (es) Vectores de vaccinia modificados.
MX2020007010A (es) Vectores modificados de orthopoxvirus.
CO2017009104A2 (es) Derivados dinucleotidos de purina bis-2’-fluoro-bis-3’-5’-cíclico
CO2019013609A2 (es) Vectores de neoantígeno de alfavirus
CL2021001178A1 (es) Procesos para la producción de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
CO2021000942A2 (es) Compuestos 1h-pyrazolo [4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y métodos y usos de los mismos
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
MX2019001672A (es) Composiciones de poxvirus quiméricos y usos de las mismas.
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
MX2017005823A (es) Metodos para transduccion y procesamiento celular.
PE20181297A1 (es) Dinucleotidos de purino ciclico como moduladores de sting
UY37563A (es) Aislados de bacillus y usos de los mismos
MY194058A (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MX2020001637A (es) Agentes de union a cd96 como inmunomoduladores.
MX393612B (es) Vacuna contra viruela para tratamiento del cancer.
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
BR112019005944A2 (pt) anticorpos que se ligam à interleucina 2 e usos dos mesmos
CO2019005714A2 (es) Estimulación nerviosa eléctrica transcutánea usando una nueva forma de onda bifásica desequilibrada y nueva disposición de electrodos.
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CO6290694A2 (es) Paramyxovirus eficaz como antitumoral
MY175423A (en) Microorganism having improved ability to produce l-lysine and method for producing l-lysine using same
MX2018007307A (es) Conjugados de peptidos y oligonucleotidos.